Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 13/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22623633 | 0.86 | CA2 (0.64) | CA2ALDH1A1MAPTHPGDTSHR | |
| SCHEMBL22623632 | 0.77 | CA2 (0.50) | CA2NR1H4ALDH1A1DDB1CRBN | |
| SCHEMBL6570475 | 0.71 | CA2 (1.00) | CA2ALDH1A1MAPTHPGDDDB1 | |
| SCHEMBL3066557 | 0.68 | CA2 (0.67) | CA2ALDH1A1MAPTHPGDTSHR | |
| SCHEMBL14622471 | 0.68 | CA2 (0.67) | CA2ALDH1A1MAPTHPGDTSHR | |
| SCHEMBL9798942 | 0.68 | CA2 (0.67) | CA2ALDH1A1MAPTHPGDTSHR | |
| SCHEMBL22623628 | 0.67 | CA2 (0.55) | CA2NR1H4ALDH1A1MAPTHPGD | |
| SCHEMBL12474357 | 0.66 | SMN1; SMN2 (0.52) | CA2ALDH1A1MAPTHPGDDDB1 | |
| SCHEMBL3626456 | 0.66 | CA2 (0.62) | CA2ALDH1A1MAPTHPGDTSHR | |
| SCHEMBL20451662 | 0.65 | ALDH1A1 (0.59) | CA2ALDH1A1MAPTHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20200347045-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | CA2 3842/4885NR1H4 1293/4885ALDH1A1 4145/4885 |
| US-20200347045-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | CA2 3842/4885NR1H4 1293/4885ALDH1A1 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.